Parallel Fluidics Touts High-Throughput LNP Automation and MilliporeSigma Collaboration at Industry Summit

Parallel Fluidics is showcasing a high-throughput, automated approach to lipid nanoparticle formulation and screening that runs on existing liquid-handling systems. The company highlighted its LNP Screening Array and automated workflows in multiple LinkedIn posts tied to the LNP Formulation Summit in Boston.

CEO and co-founder Joshua G. presented data suggesting the platform can generate more than 100 custom formulations per hour, roughly 10 times faster than some dedicated systems. The workflow is designed to use minimal sample volumes while aiming for consistent, high-quality results across leading liquid handler platforms.

Parallel Fluidics emphasized compatibility with “liquid handlers teams already run,” signaling a strategy to layer onto installed lab infrastructure rather than require new capital equipment. This cross-platform approach could reduce adoption friction for pharma, biotech, and mRNA developers seeking to scale LNP experimentation.

The company also underscored its on-stage collaboration with MilliporeSigma at the summit, pointing to increasing engagement with a major life-science tools supplier. While no formal partnership terms were disclosed, the visibility may help validate the technology and expand access to potential distribution or co-development channels.

From a financial perspective, successful validation and broader deployment of the LNP Screening Array could enhance Parallel Fluidics’ position in the growing mRNA and LNP R&D tools market. If customers confirm the reported gains in throughput and efficiency, the company may see opportunities in hardware, consumables, and workflow solutions that leverage existing automation ecosystems.

Overall, the week’s news centers on Parallel Fluidics using the LNP Summit platform to promote its automated LNP workflows, highlight performance claims, and signal deeper integration with established industry players, setting the stage for potential commercialization momentum if forthcoming data and customer adoption are favorable.